The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017:

• 33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017:
  • Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein occlusion
  • Keytruda (pembrolizumab): Used to treat non-small cell lung cancer
• 142 joint negotiations have been completed with 8 files successfully negotiated and 1 file closed since the last update of January 31, 2017:
  • Epclusa (sofosbuvir/velpatasvir): Used to treat chronic hepatitis C infection
  • Sovaldi (sofosbuvir): Used to treat chronic hepatitis C infection (second letter of intent)
  • Harvoni (sofosbuvir/ledipsavir): Used to treat chronic hepatitis C infection (second letter of intent)
  • Daklinza (daclatasvir): Used to treat chronic hepatitis C infection
  • Sunvepra (asunaprevir): Used to treat chronic hepatitis C infection
  • Plegridy (PegIFN beta-1a): Used to treat relapsing-remitting multiple sclerosis (RRMS)
  • Technivie (ombitasvir/paritaprevir/ritonavir): Used for the treatment of Hepatitis C (genotype 4)
  • Zepatier (elbasvir grazoprevir): Used for the treatment of Hepatitis C (genotype 1, 4)
  • Closed Negotiations
  • Strensiq (asfotase alfa): Used to treat hypophosphatasia
• 49 drug products for which the pCPA has decided not to negotiate collectively or individually at the  provincial-territorial level with no new files added since the last update of January 31, 2017.
• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of January 31, 2017.

For more information, please consult the pCPA’s website.